On November 17, 2026, Gain Therapeutics, Inc. announced significant findings from its Phase 1b clinical study of rexaceract, a treatment aimed at patients with Parkinson's disease. The results indicate that all 13 evaluable patients in the study completed the full 12-month administration of the drug, showing stability in motor scores and no overall disease progression.

This announcement is crucial for Gain Therapeutics as it highlights the potential efficacy of rexaceract, positioning the company favorably within the pharmaceutical preparations sector. The data suggests that the treatment is generally well tolerated, with a lower incidence of adverse events during the extended dosing period.

Background

Gain Therapeutics, Inc. operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol GANX. The firm focuses on developing innovative therapies for neurological disorders, with rexaceract being one of its key products. Recent filings include a Form 10-Q on November 10, 2026, and another 8-K on the same day, indicating ongoing activity and updates from the company.

What the Filing Says

The filing states, "As of November 1, 2026, all 13 evaluable patients in the Phase 1b clinical study have completed the full 12-month administration of rexaceract... MDS-UPDRS motor scores demonstrated stability when compared to baseline with no overall disease progression." Additionally, it notes that the treatment was well tolerated over the 12 months, with no new safety concerns identified.

Impact

The results from this study may significantly impact patients suffering from Parkinson's disease, as well as the healthcare professionals involved in their treatment. Furthermore, the findings could influence other companies in the pharmaceutical preparations sector, prompting them to evaluate their own treatment options and research initiatives.

What's Next

The filing does not say what happens next regarding further studies or potential commercialization of rexaceract.